Does adding neoadjuvant check-point inhibitor in high risk locally advanced rectal cancer increase tumour response?

ANZ J Surg. 2021 Nov;91(11):2253-2254. doi: 10.1111/ans.17150.

Authors

Joseph C Kong^{1

2

3}, Peadar Waters^{1

2

3}, Satish K Warrier^{1

2

3}, Alexander G Heriot^{1

2

3}

Affiliations

¹ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
² Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
³ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.

PMID: 34766685
DOI: 10.1111/ans.17150

No abstract available

MeSH terms

Humans
Neoadjuvant Therapy*
Neoplasm Staging
Rectal Neoplasms* / drug therapy
Rectal Neoplasms* / pathology
Rectum / pathology